Action CELSION CORPORATION
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Autres langues Celsion Corporation Nasdaq

Actions

US15117N3052

Cours en clôture Nasdaq
Autres places de cotation
- USD - Graphique intraday de Celsion Corporation
24/06 Imunon, Inc. Annonce le verrouillage de la base de données pour l'étude de phase 2 OVATION 2 avec IMNN-001 dans le cancer de l'ovaire avancé CI
05/06 IMUNON, Inc. annonce les premiers participants vaccinés dans le cadre de l'essai clinique de phase 1 IMNN-101 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
Imunon, Inc. Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
IMUNON, Inc. Announces First Participants Vaccinated in IMNN-101 Phase 1 Clinical Trial
Imunon : Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting entitled “A Phase II Study Evaluating the effect of IMNN-001 on Second Look Laparoscopy (SLL) when Administered in Combination with Bevacizumab (BEV) and Neoadjuvant Chemother
Imunon : Management Change/Compensation - Form 8-K
Imunon, Inc. Announces CFO Changes, Effective from June 1, 2024
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
Imunon, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
IMUNON, Inc. Appoints Stacy R. Lindborg as Chief Executive Officer, Effective May 13, 2024
IMUNON, Inc. Appoints Stacy R. Lindborg as President, Effective May 13, 2024
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
Imunon Receives FDA Approval to Start Phase 1 Trial of COVID-19 Booster Vaccine
Imunon Shares Rise 8% After Clearance to Start Phase 1 Trial for Covid-19 Booster Vaccine
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
Imunon, Inc. Application Cleared to Begin Human Testing of IMNN-101
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action IMNN
  4. Action
  5. Actualités Celsion Corporation
  6. Autres langues